Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) shares traded up 2.8% during mid-day trading on Monday . The stock traded as high as $20.00 and last traded at $20.00, with a volume of 55,665 shares. The stock had previously closed at $19.45.

Several research analysts have issued reports on the company. Zacks Investment Research lowered Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 7th. Wedbush reiterated a “buy” rating and issued a $36.00 price target on shares of Eiger BioPharmaceuticals in a report on Monday, June 13th. Piper Jaffray Cos. reissued a “buy” rating and issued a $33.00 price objective (up from $30.00) on shares of Eiger BioPharmaceuticals in a research note on Thursday, April 21st. Jefferies Group reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a research note on Thursday, April 14th. Finally, Oppenheimer Holdings Inc. initiated coverage on Eiger BioPharmaceuticals in a research note on Tuesday, July 5th. They issued an “outperform” rating and a $34.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $34.50.

The firm’s market capitalization is $136.96 million. The company’s 50 day moving average price is $19.44 and its 200 day moving average price is $18.53.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Monday, May 16th. The company reported ($10.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by $8.73. On average, analysts anticipate that Eiger BioPharmaceuticals Inc. will post ($7.88) EPS for the current fiscal year.

In other news, CFO James H. Welch acquired 2,500 shares of the business’s stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average cost of $19.80 per share, with a total value of $49,500.00. Following the transaction, the chief financial officer now owns 2,000 shares in the company, valued at approximately $39,600. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James P. Shaffer acquired 1,250 shares of the business’s stock in a transaction on Monday, June 13th. The shares were purchased at an average cost of $22.17 per share, for a total transaction of $27,712.50. Following the completion of the transaction, the insider now owns 1,975 shares in the company, valued at approximately $43,785.75. The disclosure for this purchase can be found here.

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.